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ABSTRACT
In this study, thiourea derivatives [1-4] were synthesized 
by using 2-amino-4-substituted pyridine compounds and 
these compounds have been used as the starting materials for 
synthesis of 2-imino-1,3-thiazolidin-4-one ring [5, 6]. Two 
different procedures for 4-thiazolidinone ring closure and 
synthesis method were optimized. The synthesized compounds 
were identified by the help of elemental analysis, IR, 1H-NMR, 
13C-NMR and mass spectral data while the purities of them were 
proved with TLC. Synthesized compounds were evaluated for 
their antiviral and anticancer activity. Antiviral activity against 
Murine norovirus, Yellow fever, Enterovirus and Chikungunya 
strains of the test compounds were investigated and EC50 values 
of these compounds were determined higher than 0,3 µM. 
Cytotoxicity of test compounds was examined on NIH3T3 
cell line. When the anticancer activity of test compounds was 
examined against PC-3, A549, HeLa, HT-29, MCF-7, SJSA1 
and K562 cell lines, the percent proliferation values of these 
compounds were observed over 61% for all cell lines.
Keywords: Acylthioureas; anticancer; antiviral; tautomerism; 
thiourea; 2-amino-1,3-thiazol-4-one; 2-imino-1,3-thiazolidin-
4-one.
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1. INTRODUCTION
Cancer is expressed as an uncontrolled cell division and 
spread of abnormal cells whose normal cellular functions 
are damaged. Furthermore, cancer is a major health problem 
worldwide and seen as the second cause of death after 
cardiovascular diseases (1). Recently, some research studies 
have shown that infections with some parasites, viruses and 
bacteria are risk factors for several types of cancer in humans. 
Infectious agents such as hepatitis B virus (HBV), hepatitis 
C virus (HCV) and human immunodeficiency virus (HIV) 
have been found to be associated with many cancers (2). The 
relationship among inflammation, infection which is caused 
by a virus, and cancer makes it important to discover new 
antiviral and anti-inflammatory agents.
Many studies have shown that thioureas have a broad 
spectrum of biological effects profile including antiviral 
(3), antitubercular (4, 5), antibacterial (6), antifungal (7), 
antimycobacterial (8), anti-inflammatory (9), anticancer 
(10), antitumor (11) and antimalarial (12) activity.
Thiourea is a versatile reagent for the synthesis chemistry and 
is an important building block in the synthesis of heterocyclic 
compounds. Acyl thiourea derivatives have increasing 
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importance due to the electronic structure of these molecules, 
resulting in their wide biological effect spectrum and 
biologically active metal complex. Acyl thiourea compounds, 
cambinol and tenovin-1 are small molecule inhibitors of the 
NAD+-dependent family of protein deacetylases that is one of 
the targets in the treatment of cancer and neurodegenerative 
diseases (13, 14). In the other research, CID 1067700 carrying 
acyl thiourea structure has been reported as an inhibitor of 
nucleotide binding by Ras-related GTPases (15). In addition, 
N-substituted phenylthioureas have been found that have 
antitumoral effects against skin cancer (16, 17).
4-Thiazolidinone derivatives among heterocyclic ring 
systems have been reported to possess various biological 
properties such as anticancer (18), anti-inflammatory (19, 
20), antibacterial (21, 22), antioxidant (23), anticonvulsant 
(24), antiviral (25), antimicrobial (26) and antifungal 
activities (27). The following 1,3-thiazolidin-4-on derivatives 
are used in medicine: ralitoline (anticonvulsant), piprozolin 
(choleretic), etozolin, ozolinone (diuretic), dexetozolin 
(antihypertensive), mezolidon (antiulcer) (28-30).
Different tautomers of the same compounds may have 
various biological effects from each other and identification 
of tautomerism is quite important for the heteroaromatic 
system. Aromaticity of heteroaromatic system for a drug with 
an amino-imino tautomerism is affected by this tautomerism 
and biological effects may change with new groups that have 
capable of H-bonding interaction, formed by tautomerism 
(31). In this study, our aim is to synthesize 2-imino-1,3-
thiazolidin-4-on derivatives using two different procedures 
and to examine the tautomerism of synthesized compounds. 
Besides, we decided to evaluate the antiviral and anticancer 
activity of the synthesized thiourea and 4-thiazolidinone 
derivatives.
2. RESULTS AND DISCUSSION
2.1. Chemistry
There are several methods used for the synthesis of 
thiazolidinone derivatives. One of these methods is 
cyclization of chloroacetamides in the presence of ammonium 
thiocyanate (32, 33) while the other one is cyclization of 
thioureas with ethyl bromoacetate in the presence of sodium 
acetate (34, 35). Synthesized 4-thiazolidinone derivatives by 
using different methods have five possible tautomeric forms 
and these forms are given in Figure 3 (36).
2-Imino-1,3-thiazolidin-4-one derivatives are our target 
compounds in this study and one of the tautomers of 
4-thiazolidinone ring. We have synthesized these compounds 
by using two different methods as given in Scheme 1. We 
have at first preferred the cyclization of chloroacetamides 
to synthesize these compounds in the presence of 
NH4SCN. Synthesis of 2-chloro-N-[4-methylpyridin-2-yl]
acetamide was carried out by the reaction of 2-amino-4-
methylpyridine (5 mmol) with chloroacetyl chloride (6 
mmol) in the presence of TEA (6 mmol) and DCM (15 ml) 
at 50-60ºC. Red powder substance was obtained with a yield 
of 35% and melting point of this compound was observed 
as 114ºC (37). A solution of 2-chloro-N-[4-methylpyridin-
2-yl]acetamide (5 mmol) and ammonium thiocyanate (10 
mmol) in 20 ml absolute ethanol were refluxed for 6 h and 
the crude product was obtained by evaporating ethanol. 
Compound 5’ was obtained as a brown powder with a yield 
Figure 1. Biologically active acyl thiourea derivatives.
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Figure 2. Drugs bearing 1,3-thiazolidin-4-one ring used in medicine.
Figure 3. Tautomeric forms of 1,3-thiazolidin-4-one ring system.
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of 52% and melting point of this compound was observed 
between 241-243ºC. Positive and negative ion mass spectra 
of compound 5’ were obtained by using electrospray 
ionization technique. Molecular ion peak of compound 5’ 
was observed at 205.929 Da (calculated: 206.039 Da) for 
negative ion spectra and 207.965 Da (calculated: 208.054 
Da) for positive ion spectra.
At the same time, the target compound 5 was synthesized 
performing a stepwise reaction protocol from N-(4-
methylpyridine-2-yl)thiourea as outlined in Scheme 1 and 
we compared physical and spectral findings of compounds 
5 and 5’.
When 1H-NMR spectrum of compound 5’ is examined, two 
peaks with 2H and 1H integrations were detected for -CH2- 
protons located in the fifth position of 4-thiazolidinone ring 
at 3.81 ppm and 3.71 ppm, respectively (38, 39) while signals 
at about 2.47 ppm with 3/2H integration and 2.32 ppm with 
3H integration that were attributed to the –CH3 protons 
located in the fourth position of pyridine. In addition, two 
N-H peaks with 1H and 1/2 H integrations were detected 
at 11.95 ppm and 9.62 ppm, respectively (Figure 4). Since 
it is known that N-H peak was observed about 12 ppm and 
9-10 ppm for 2-imino-1,3-thiazolidin-4-one (40, 41) and 
2-amino-1,3-thiazol-4(5H)-one (42), respectively, these 
findings showed that these tautomeric forms were together 
with 1:2 ratio in our synthesized product. After these 
results, we decided to synthesize 1,3-thiazolidin-4-one ring 
by using the other method that cyclization of thioureas with 
ethyl bromoacetate in the presence of sodium acetate in 
ethanol. White powder substance was obtained with a yield 
of 74% and melting point of this compound was observed 
as 244ºC. When we compared IR spectra of compound 5 
and 5’, we saw that there was 93% similarity between these 
spectra (Figure 5).
When 1H-NMR spectrum of compound 5 is examined, 
signals at 3.81 ppm and 2.31 ppm were attributed to 
the -CH2- and –CH3 protons, respectively. Moreover, 
we observed a broad singlet peak for N-H proton of 
4-thiazolidinone ring at 11.92 ppm that was noticed to 
exchange with D2O in the 1H NMR spectrum (Figure 4). 
As a result, we determined that 2-imino tautomeric form is 
obtained by cyclization of thioureas whilst mixture of two 
tautomeric forms is obtained by using chloroacetamides as 
a starting compound (Scheme 1).
Scheme 1. Two different synthesis procedures for 1,3-thiazolidin-4-one ring.
Reagents and conditions: a) ClCOCH2Cl, TEA, DCM; b) NH4SCN, EtOH, reflux; c) NH4SCN, C6H5COCl, dry acetone, 80°C reflux; d) 1N 
NaOH, MeOH, 100°C, reflux; e) CH3COONa, BrCH2COOC2H5, EtOH, 100°C, reflux. (R=CH3 for compounds 1,3,5 ; R=Cl for compounds 
2,4,6)
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Figure 4. A) 1H-NMR Spectrum of compound 5’, B) 1H-NMR Spectrum of compound 5, C) D2O Exchange spectrum of 
compound 5.
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Figure 5. Comparison of  IR spectra of compounds 5 and 5’.
Table 1. Physical and analytical data of compounds 5 and 5’.
Compound 5’ Compound 5
Yield (%) 52 74
Appearance Brown powder substance White powder substance
M.p. (°C) 241-243 244
Rf
[petroleum ether - acetone (30:70, v/v)] 0.49 0.49
Elemental analysis
(Calculated / Found)
C 48.68* / 48.91 52.16 ** / 51.72
H 4.99 / 4.58 4.38 / 4.65
N 18.92 / 18.32 20.27 / 20.04
S 14.44 / 13.21 15.47 / 15.20
* Calculated according to C9H9N3OS . 4/5 H2O
** Calculated according to C9H9N3OS
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In the light of these findings, we decided to synthesize the 
target compounds by using thioureas as starting materials. 
N-(4-Substituted pyridine-2-yl)thioureas [3, 4] were 
obtained by hydrolysis of N-(4-substituted pyridine-2-yl)-
N’-benzoyl thioureas [1, 2] which were synthesized from 
2-amino-4-methylpyridine and 2-amino-4-chloropyridine 
as starting compounds. 2-Imino-1,3-thiazolidin-4-one [5, 6] 
derivatives were obtained by heating the compound 3 and 4 
with ethyl bromoacetate in the presence of sodium acetate in 
ethanol.
All synthesized compounds were checked for purity and 
identity using TLC and elemental analysis. All newly 
synthesized compounds were characterized by their melting 
points, FTIR, 1H NMR and mass spectral data, whereas 13C 
NMR spectra were also recorded for compounds 5 and 6.
The IR spectra of compounds 1 and 2 have C=O, C=S and 
N-H stretching bands of acylthiourea group at 1674-1675 cm-
1, 1237-1249 and 1165 cm-1, and 3256-3274 cm-1, respectively 
(7, 43). In the 1H-NMR spectra of compound 2, resonances 
assigned to the N1-H and N2-H protons of thiourea were 
detected between 8.83-13.28 ppm as three broad singlets, 
which are supported by the literature (7, 44, 45). When we 
examined the IR spectra of compounds 3 and 4, we detected 
two C=S stretching bands at 1106-1170 cm-1 and 1216-1235 
cm-1, and N-H stretching bands at 3084-3188 cm-1, whereas 
C=O stretching bands of the acylthioureas disappeared. In the 
1H-NMR spectra of compound 4, NH proton of thiourea was 
observed at 10.65 ppm while NH2 protons have two singlet 
peaks at 9.05 ppm and 10.38 ppm (46). In the IR spectra of 
compounds 5 and 6, the disappearance of C=S stretching 
bands of the thioureas, detection of C=O stretching band and 
C-S-C stretching band at 1678-1694 cm-1 and 666-669 cm-1, 
respectively (32, 47) and observation of thiazolidinone NH 
peak at 11.92 ppm in the 1H-NMR spectra of compound 5 is 
an evidence for ring closure form of 2-imino-1,3-thiazolidin-
4-one. Another support for 2-imino-1,3-thiazolidin-4-one 
ring closure was the detection of a signal at 3.81-3.87 ppm, 
due to the presence of -CH2- protons located in the fifth 
position of the 4-thiazolidinone ring, furthermore, NH 
proton of compound 5 was observed to exchange with D2O 
in the spectrum. 13C-NMR spectra of compounds 5 and 6 
showed the presence of new carbonyl peak (C=O) due to 
4-thiazolidinone ring at 172.72 ppm. Moreover, the chemical 
shift of -CH2- carbon for these compounds were detected 
in the range of 35.60-36.37 ppm (48). The mass spectral 
analysis of the synthesized compounds was performed 
under electro-spray ionization. Mass spectra confirmed the 
molecular weights and empirical formula of compounds 
1-6 for both negative and positive ion mass spectra. Our 
target compounds that are 2-imino-1,3-thiazolidinones gave 
elemental analysis data consistent to assigned structures.
2.2. Biological Activity Studies
2.2.1. Antiviral Activity
Results of antiviral assays against Murine norovirus, Yellow 
fever virus, Enterovirus and Chikungunya virus strains for 
synthesized compounds 1-6 were given in Table 2. EC50 
values for all strains of these compounds were determined 
higher than 0.3 µM. EC50 value of compounds 2 and 6 could 
not be calculated for Yellow fever virus and Enterovirus, 
respectively because their dose-response curve did not show 
a linear increase in studied concentration range. Tested 
compounds did not show 50 % or higher antiviral activity 
than the control group for all strains in studied concentration 
range, so their cytotoxicity could not be calculated.
Table 2. Results of antiviral activity for all synthesized compounds.
Compound Murine norovirus Yellow fever Enterovirus Chikungunya
EC50 (µM) CC50 (µM) EC50 (µM) CC50 (µM) EC50 (µM) CC50 (µM) EC50 (µM) CC50 (µM)
1 >0.4 0.2±0 >0.4 >0.4 >0.4 >0.4 >0.4 >0.4
2 >0.3 0.2±0 - >0.3 >0.3 >0.3 >0.3 >0.3
3 >0.6 0.1±0.03 >0.6 >0.6 >0.6 >0.6 >0.6 >0.6
4 >0.5 0.2±0.08 >0.5 0.2±0.02 >0.5 >0.5 >0.5 >0.5
5 >0.5 0.2±0.07 >0.5 0.2±0.0001 >0.5 >0.5 >0.5 >0.5
6 >0.4 0.1±0.07 >0.4 >0.4 - >0.4 >0.4 0.2±0.03
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2.2.2. Anticancer Activity
In this study, human chronic myeloid leukemia cell line K562 
(ATCC, CCL243), human breast cancer cell line MCF-7 
(ATCC, HTB22), human colon cancer cell line HT-29 (ATCC, 
HTB-38), human osteosarcoma cell line SJSA1 (ATCC, CRL-
2098) human lung cancer cell line A549 (ATCC, CCL-185), 
human prostate cancer cell line PC-3 (ATCC, CRL-1435), 
human cervical carcinoma cell line HeLa (ATCC, CCL-2) 
were used and proliferation values of test compounds were 
evaluated at 10 µM dose (Tablo 3). Additionally, cytotoxicty 
results against mouse fibroblast cell line NIH3T3 (ATCC, 
CRL-1658) at 10 µM dose of compounds 1-6 were given in 
Table 3 and their proliferation values were observed in the 
range of 29.79-98.19 %. The most active compound was 
identified as compound 4 by 38.92% and 35.96% inhibition in 
HT-29 and SJSA1 cell lines, respectively. This compound was 
observed non-toxic to NIH3T3 mouse fibroblast cells with 
high survival rate (92.01%). Other remarkable inhibitions 
were observed with compounds 2 (32.29% inhibition vs. HT-
29) and 6 (35.82% inhibition vs. HeLa) at 10 µM dose. These 
compounds appeared as safe towards NIH3T3 fibroblasts.
2.3. Prediction of Drug-Likeness and Absorption, 
Distribution, Metabolism, and Excretion (ADME) 
Properties of Compounds 1-6.
Oral bioavailability and appropriate drug delivery are 
quite important for new drug candidates intended for 
oral use (49). Many of the drug candidates with poor 
pharmacokinetic profiles fail at development stages (50). 
A low and variable bioavailability is not a desired property 
in the development of a drug candidate (51). Accordingly, 
a computational study for prediction of ADME properties 
of the molecules was performed by using Molinspiration 
online property calculation toolkit for determination of 
topological polar surface area (TPSA), absorption (%ABS), 
lipophilicity and simple molecular descriptors used by 
Lipinski in formulating his “rule of five” (52, 53). Table 4 
represents a calculated percentage of absorption (%ABS), 
topological polar surface area (TPSA) and Lipinski 
parameters of the compounds 1-6. Percentage of absorption 
(%ABS) was estimated using the equation: %ABS=109-
(0.345xTPSA), according to Zhao et al (54). TPSA was also 
calculated using Molinspiration online property calculation 
toolkit according to the fragment-based method of Ertl et 
al (55). Polar surface area, together with lipophilicity, is 
an important property of a molecule in transport across 
biological membranes. Too high TPSA values give rise to a 
poor bioavailability and absorption of a drug. According to 
the above criterions, calculated percentages of absorption 
for compounds 1-6 ranged between 90.3 and 91.4%. 
Number of hydrogen bond acceptors varied 3 to 4 while 
the number of hydrogen bond donors varied 1 to 3 for 
all synthesized compounds. All these findings related to 
Lipinski parameters showed that compounds 1-6 have zero 
violations to Lipinski rule of five.
Table 3. Cytotoxicity and anticancer activity of compounds 1-6 in selected cancer cell lines.
% Proliferation (at 10 µM dose)
Compound NIH3T3 PC-3 A549 HeLa HT-29 MCF-7 SJSA1 K562
1 29.79 78.11 80.12 100.17 89.44 113.08 81.51 99.19
2 78.12 93.41 89.29 78.77 67.71 91.61 79.87 102.52
3 48.17 70.03 73.26 99.63 89.72 107.44 89.85 98.34
4 92.01 77.26 76.26 80.89 61.08 79.60 64.04 113.51
5 75.73 78.85 82.09 121.72 89.11 108.47 92.63 105.75
6 98.19 82.47 74.46 64.18 81.81 97.97 81.26 109.22
Table 4. Predicted ADME, Lipinski parameters and molecular properties of compounds 1-6.
Compound MW Volume TPSA %ABS n-ROTB n-ON n-OHNH mi LogP n Violations
1 271.35 239.51 54.02 90.4 4 4 2 2.52 0
2 291.76 236.48 54.02 90.4 4 4 2 2.75 0
3 167.24 148.00 50.94 91.4 2 3 3 1.11 0
4 187.66 144.97 50.94 91.4 2 3 3 1.34 0
5 207.26 175.18 54.35 90.3 1 4 1 0.92 0
6 227.68 172.16 54.35 90.3 1 4 1 1.14 0
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3. CONCLUSION
In conclusion, we used two different synthesis procedures for 
4-thiazolidinone ring closure and compared the structure of 
the obtained compounds by using physical, analytical and 
spectral data. So we determined that 2-imino tautomeric 
form is obtained by cyclization of thioureas even though 
a mixture of two tautomeric forms is obtained by using 
chloroacetamides as a starting compound. As a result, we 
observed that different tautomers of the 4-thiazolidinone 
ring could be obtained when the synthesis method was 
changed.
Biological properties of compounds 1-6 were evaluated as 
anticancer and antiviral agents. Antiviral activity against 
Murine norovirus, Yellow fever virus, Enterovirus and 
Chikungunya virus strains of the all synthesized compounds 
were evaluated but a significant antiviral activity at subtoxic 
concentrations was not observed. Cytotoxic property against 
NIH3T3 cell line and anticancer activity against K562, MCF-
7, HT-29, SJSA1, A549, PC-3, HeLa cell lines of compounds 
1-6 were evaluated at 10 µM dose. Non-toxic compounds 2 
(against HT-29 cell line), 4 (against HT-29 and SJSA1 cell 
lines) and 6 (against HeLa cell line) showed that cell growth 
inhibition between 32.29 and 38.92%.
4. MATERIAL AND METHODS
4.1. Synthetic Chemistry
All solvents and reagents were obtained from commercial 
sources and used without purification. The purity 
of the compounds was confirmed by the thin-layer 
chromatography (TLC) performed on Merck silica gel 60 
F254 aluminum sheets (Merck, Darmstadt, Germany), using 
developing systems: S1: petroleum ether/acetone (60:40 
v/v); S2: dichloromethane/ethyl acetate/ethanol (60:30:10 
v/v/v) and S3: petroleum ether /acetone (30:70 v/v) . Spots 
were detected under UV light at λ= 254 and 366 nm. All 
melting points (ºC, uncorrected) were determined using 
Schmelzpunktbestimmer SMP II basic model melting point 
apparatus. Elemental analyses were obtained using Leco 
CHNS-932 and are consistent with the assigned structures. 
Infrared spectra were recorded on a Shimadzu FTIR 8400S 
and data are expressed in wavenumbers ν (cm-1). NMR 
spectra were recorded on Brüker 300 MHz Ultrashield 
TM at 300 MHz for 1H-NMR and 600 MHz for 13CNMR 
(decoupled), the chemical shifts were expressed in δ (ppm) 
downfield from tetramethylsilane (TMS) using DMSO-d6 as 
solvent. ESI positive and negative ionization (low resolution) 
mass spectra of the synthesized compounds were obtained 
using AB SCIEX API 2000 LC–MS/MS instrument.
General procedure for the synthesis of N-(4-substituted pyridin-
2-yl)-N’-benzoyl thioureas [1-2]
A solution of benzoyl chloride (0.012 mol) in dry acetone (30 
ml) was added, dropwise, to a suspension of NH4SCN (0.0132 
mol) in acetone (20 ml). The mixture was stirred until the 
formation of benzoyl isothiocyanate for 1 h. Then 2-amino-
4-substituted pyridine derivative (0.01 mol), dissolved in 
acetone (20 ml) was slowly added to the reaction flask, with 
constant stirring. The solution was heated under reflux for 
3 h. The reaction mixture was then poured onto ice. Solids 
of N-(4-substituted pyridin-2-yl)-N’-benzoyl thioureas were 
collected by filtration and finally purified by recrystallization 
from methanol.
N-[(4-Methylpyridin-2-yl)carbamothioyl]benzamide [1]
Yield 74%. M.p. 165ºC (lit.154-155ºC (56)). TLC Rf: 0.58 
(S1). IR, ν (cm-1): 3274 (NH str), 1674 (C=O str), 1249, 1165 
(C=S str). LC–MS-(ESI): Calculated: Mmi: 271.078, (M+H)+: 
272.085, (M-H)-: 270.071. Found: (M+H)+: 272.004, (M-H)-: 
270.123.
N-[(4-Chloropyridin-2-yl)carbamothioyl]benzamide [2]
Yield 70%. M.p. 145-146ºC. TLC Rf: 0.85 (S2). IR, ν (cm-
1): 3256 (NH str), 1675 (C=O str), 1237, 1165 (C=S str). 
1H NMR, δ (ppm): 7.43-7.45 (dd, J=5.4 Hz and 1.8 Hz, 1H, 
Pyr-H), 7.54-7.72 ( m, 4H, Pyr-H and Ar-H), 7.97-8.00 (m, 
2H, Ar-H), 8.44 (d, J=5.4 Hz, 1H, Pyr-H), 8.83 (br s, NH), 
12.05 (br s, NH), 13.28 (br s, NH). LC–MS-(ESI): Calculated: 
Mmi: 291.023, (M+H)+: 292.031. Found: (M+H)+: 291.976.
General procedure for the synthesis of N-(4-substituted pyridin-
2-yl)thioureas [3-4]
Compound 1 or 2 (0.005 mol) was dissolved in methanol (20 
ml) and solution of aqueous sodium hydroxide (1N) (5 ml) 
was added. The solution was heated under reflux for 6 h, then 
the mixture was poured onto crushed ice and neutralized 
with 1N hydrochloric acid (pH~7). The precipitated crude 
product was washed with water and purified by crystallization 
with methanol.
N-(4-Methylpyridin-2-yl)thiourea [3]
Yield 84%. M.p. 220-222ºC (lit.210-212ºC (57)). TLC Rf: 0.48 
(S1), 0.64 (S3). IR, ν (cm-1): 3219, 3189 (NH str), 1235, 1170 
(C=S str). LC–MS-(ESI): Calculated: Mmi: 167.052, (M+H)+: 
168.059, (M-H)-: 166.044. Found: (M+H)+: 168.114, (M-H)-: 
165.965.
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N-(4-Chloropyridin-2-yl)thiourea [4]
Yield 75%. M.p. 197ºC. TLC Rf: 0.75 (S2). IR, ν (cm-1): 3265, 
3112 (NH str), 1216, 1106 (C=S str). 1H NMR, δ (ppm): 7.16-
7.19 (dd, J=5.6 Hz, 2.1 Hz and 1.8 Hz, 1H, Pyr-H), 7.27 (d, 
J=1.5 Hz, 1H, Pyr-H), 8.23 (d, J=5.4 Hz, 1H, Pyr-H), 9.05 (br 
s, NH), 10.38 (br s, NH), 10.65 (br s, NH). LC–MS-(ESI): 
Calculated: Mmi: 186.997, (M+H)+: 188.004, (M-H)-: 185.990. 
Found: (M+H)+: 188.031, (M-H)-: 186.055.
General procedure for the synthesis of 2-[(4-substituted 
pyridin-2-yl)imino]-1,3-thiazolidin-4-one [5-6]
Anhydrous sodium acetate (0.02 mol) and ethyl bromoacetate 
(0.005 mol) were added into the ethanolic solution of 
compound 3 or 4 (0.005 mol). The reaction mixture was 
boiled for 7 h under reflux conditions. At the end of the 
reaction, the substance precipitated at room temperature was 
filtered, dried and purified by crystallization with ethanol.
(2Z)-2-[(4-Methylpyridin-2-yl)imino]-1,3-thiazolidin-4-one [5]
Yield 74%. M.p. 244ºC. TLC Rf: 0.49 (S3). IR, ν (cm-1): 
3157 (NH str), 1678 (C=O str), 666 (C-S-C str). 1H NMR, 
δ (ppm): 2.31 (s, 3H, -CH3), 3.81 (s, 2H, S-CH2-), 6.93-6.98 
(m, 2H, Pyr-H), 8.23 (d, J=5.4 Hz, 1H, Pyr-H), 11.92 (br s, 
1H, thiazolidinone NH). 13C NMR, δ (ppm): 21.01 (CH3), 
36.37 (SCH2), 118.15, 120.69, 146.89, 149.46 (Pyr-C), 172.82 
(C=O). Anal. calc. for C9H9N3OS (207.25 g/mol): C, 52.16; H, 
4.38; N, 20.27; S, 15.47%. Found C, 51.72; H, 4.65; N, 20.04; 
S, 15.20%. LC–MS-(ESI): Calculated: Mmi: 207.047, (M+H)+: 
208.054, (M-H)-: 206.039. Found: (M+H)+: 208.068, (M-H)-: 
205.933.
(2Z)-2-[(4-Chloropyridin-2-yl)imino]-1,3-thiazolidin-4-one [6]
Yield 68%. M.p. 267ºC. TLC Rf: 0.53 (S2). IR, ν (cm-1): 3148 
(NH str), 1694 (C=O str), 669 (C-S-C str). 1H NMR, δ (ppm): 
3.87 (s, 2H, S-CH2-), 7.24-7.26 (m, 2H, Pyr-H), 8.37 (d, J=6 
Hz, 1H, Pyr-H). 13C NMR, δ (ppm): 35.60 (SCH2), 118.46, 
120.05, 144.59, 148.70 (Pyr-C). Anal. calc. for C8H6ClN3OS 
(227.67 g/mol): C, 41.55; H, 2.79; N, 18.17; S, 13.86%. 
Found C, 41.95; H, 2.75; N, 17.89; S, 13.37%. LC–MS-(ESI): 
Calculated: Mmi: 226.992, (M+H)+: 227.999, (M-H)-: 225.985. 
Found: (M+H)+: 228.035, (M-H)-: 225.996.
4.2. Biological Methods
4.2.1. Antiviral Assays
The antiviral activity of the selected compounds against 
the different viruses was determined using an MTS 
[3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-
2-(4-sulfophenyl)-2H-tetrazolium]-based cytopathic effect 
(CPE) reduction assay. Antiviral assays were performed in 
DMEM medium supplemented with 2% FCA and other 
components depending on the cell line. Cells were seeded 
in a 96-well plate (Falcon, BD Biosciences) and allowed 
to adhere overnight. The next day they were infected with 
virus in the presence (or absence) of a dilution series of 
compounds. Cells were incubated (37°C, 5% CO2, 95-99% 
relative humidity) until complete CPE was observed in 
infected untreated cells. Subsequently, the assay medium 
was aspirated, replaced with 75 µl of a 5% MTS (Promega) 
solution (MTS-phenazinemethosulfate (MTS/PMS) stock 
solution [(2 g/L MTS (Promega, Leiden, The Netherlands) 
and 46 mg/L PMS (Sigma–Aldrich, Bornem, Belgium) in PBS 
at pH 6–6.5)] was diluted 1/20 in MEM (Life Technologies, 
Gent, Belgium)) in phenol red-free medium, and incubated 
for 1.5 h. Absorbance was measured at a wavelength of 498 
nm (Safire2, Tecan), with the optical densities (OD values) 
reaching 0.6-0.8 for the untreated, uninfected controls. The 
optical density values were converted to control percentages 
and logarithmic interpolation was used to calculate the EC50 
and CC50.
The EC50 was defined as the compound concentration that 
(i) protected 50% of cells from virus-induced CPE or (ii) 
reduced RNA copies by 50%. Adverse effects of the drug on 
the host cell were also assessed by means of the MTS method, 
by exposing uninfected cells to the same concentrations of 
the compounds. The CC50 was defined as the compound 
concentration that reduced the number of viable cells by 50%.
4.2.1.1. Chikungunya Virus-Cell-Based Antiviral Assay
Chikungunya virus (Indian Ocean strain 899), kindly 
provided by C. Drosten (Institute of Virology, University 
of Bonn, Germany), was grown on Vero A cells. Serial 
dilutions of the test compounds were made in 100 µl assay 
medium [MEM Rega3 (cat. no. 19993013; Invitrogen), 2% 
FCS (Integro), 5 ml of 200 mM L-glutamine, and 5 ml of 
7.5% NaHCO3] in a 96-well microtiter. Subsequently, 50 µl 
of a 4 x virus dilution in assay medium was added, followed 
by 50 µl of a cell suspension. This suspension, with a cell 
density of 25 000 cells/50 µl, was prepared from a Vero A 
cell line subcultured in cell growth medium (MEM Rega3, 
supplemented with 10% FCS, 5 ml of L-glutamine, and 5 ml 
NaHCO3) at a ratio of 1:4 and grown for 7 days in 150 cm2 
tissue culture flasks (Techno Plastic Products). The assay 
plates were returned to the incubator for 6-7 days a time at 
which maximal virus-induced cell death or cytopathic effect 
(CPE) is observed in untreated, infected controls.
Kulabaş et al.
Thioureas, acylthioureas and 4-thiazolidinones as anticancer and antiviral agentsMarmara Pharm J 21/2: 371-384, 2017 381
4.2.1.2. Norovirus-Cell-Based Antiviral Assay
RAW 264.7 cells (1 x 104 cells/well) were seeded in a 96-well 
plate in 100 µl medium (DMEM medium supplemented 
with 10% FCS, 1% NaHCO3, 1% L-glutamine, 1% sodium 
pyruvate, 1% P/S and 2% Hepes) and infected with MNV 
(virus strain MNV-1.CW1 kindly provided by Dr. Herbert 
Virgin, Washington University, St. Louis, USA) at a 
multiplicity of infection (MOI) of 0.001 in the presence 
(or absence) of a dilution series of compounds. Cells were 
incubated for 3 days, i.e. until complete CPE was observed in 
infected untreated cells.
4.2.1.3. Enterovirus-Cell-Based Antiviral Assay
Enterovirus 71 strain BrCr (EV71 BrCr), a gift from F. van 
Kuppeveld (Universiteit Utrecht, The Netherlands), was 
grown on RD cells. Cells were seeded at a density of 2.5 x 
104 cells per well (100 µL) in 96-well cell culture plates. 
These assays were performed using MEM Rega3 medium 
supplemented with 2% FBS, 2 mM-glutamine and 0.075% 
NaHCO3. Cells were allowed to adhere overnight, after which 
serial dilutions of the compound were made in the supernatant 
and 100 µl of a 2 x virus dilution in assay medium was added. 
The cultures were subsequently incubated for 4 days at 37°C, 
until complete virus-induced CPEs were observed in the 
untreated and infected virus control conditions (VC).
4.2.1.4. Yellow Fever Virus-Cell-Based Antiviral Assay
Yellow Fever Virus (Stamaril; Aventis Pasteur MSD, Brussels, 
Belgium) was grown on Huh-7 cells. Cells were seeded at a 
density 5.5 x 103 cells/well in 100 µL assay medium (DMEM 
medium supplemented with 10% FCS, 1% NEAA and 2% 
Hepes) in 96-well cell culture plates and allowed to adhere 
overnight. Antiviral assays were performed in DMEM medium 
supplemented with 2% FCS, 1% NEAA and 2% Hepes.
Serial dilutions of the compound were made in the supernatant 
and 100 µl of a 2 x virus dilution in assay medium was added. 
The cultures were subsequently incubated for 5 days at 37°C, 
until complete virus-induced CPEs were observed in the 
untreated and infected virus control conditions (VC).
4.2.2. Anticancer Assay
4.2.2.1. Cell culture
Human breast cancer cell line MCF-7 (ATCC, HTB22), 
human colon cancer cell line HT-29 (ATCC, HTB-38), 
human osteosarcoma cell line SJSA1 (ATCC, CRL-2098) 
human lung cancer cell line A549 (ATCC, CCL-185), 
human prostate cancer cell line PC-3 (ATCC, CRL-1435), 
human cervical carcinoma cell line HeLa (ATCC, CCL-
2), human leukemic cell line, K562 (ATCC, CCL-243) and 
mouse fibroblast cell line NIH3T3 (ATCC, CRL-1658) were 
maintained in DMEM (Dulbecco’s Modified Eagle Medium) 
supplemented with 10% FBS (Fetal bovine serum), 1% 
L-Glutamine and penicillin/streptomycin (Gibco) at 37°C in 
a humidified incubator with 5% CO2.
4.2.2.2. Cell viability assay
Cell viability was determined by the 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. 
Briefly, the cells (1 × 104 cells/well) were seeded onto 96-
well plates and incubated overnight. Then, the cells were 
treated with compounds (at 10 µM concentration) for 48 h. 
After the incubation period, MTT was added into each well 
to a final concentration of 0.5 mg/mL and incubated for 4 
h. The culture medium was then removed and 100 μL of 
the SDS buffer was added to solubilize the purple formazan 
product. Absorbances at wavelengths of 570 and 630 nm 
were measured by a microplate reader (Biotek, Winooski, 
VT).
For human leukemic cell line, K562 (ATCC, CCL-243) 
cells, 200 µl (1x104 cells) of cell suspension was plated in 
each well of a 96-well plate. After the incubation for 12 
h, the cells were treated with 10 µM concentrations of 
compounds. An equal volume of DMSO was added to the 
control wells, and the cells were cultured an additional 32 h. 
After the incubation period, 20 µL MTT was added to each 
well to a final concentration of 5 mg/mL and incubated at 
37 ⁰C for 4 h. Plates were then centrifuged at 400 × g for 
10 min. Supernatants were removed from the wells and 
200 μL of the SDS buffer was added into wells to solubilize 
the purple formazan product. Absorbances at wavelengths 
of 570 and 630 nm were measured by a microplate reader 
(Biotek, Winooski, VT, USA).
Viability was calculated as follows: Cell Viability (%)= (OD 
test /OD control) x 100%.
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Tiyoüreler, açiltiyoüreler ve 4-tiyazolidinonların sentezi, 
karakterizasyonu ve antikanser ve antiviral etkilerinin 
değerlendirilmesi
ÖZET
Bu çalışma kapsamında 2-amino-4-sübstitüe piridin 
bileşiklerinden hareketle sentezlenen tiyoüre türevleri [1-
4], 2-imino-1,3-tiyazolidin-4-on halkalarının [5, 6] sentez 
başlangıç maddelerini oluşturmaktadır. 4-Tiyazolidinon halka 
kapaması ve sentezi için iki farklı yöntem optimize edilmiştir. 
Sentezlenen bileşiklerin yapıları elementel analiz, IR, 1H-NMR, 
13C-NMR ve kütle spektrumu ile kanıtlanmış, saflıkları ise 
İTK ile kontrol edilmiştir. Elde edilen bileşikler antiviral ve 
antikanser etkinlikleri açısından değerlendirilmiştir. Murine 
norovirus, Yellow fever, Enterovirus ve Chikungunya suşlarına 
karşı antiviral etkileri incelenen bileşiklerin 0,3 µM’dan yüksek 
EC50 değerine sahip oldukları tespit edilmiştir. Sitotoksisiteleri 
NIH3T3 hücre hattı üzerinde incelenen bileşiklerin antikanser 
etkileri PC-3, A549, HeLa, HT-29, MCF-7, SJSA1 ve K562 
hücre hatlarına karşı incelenmiş %61’in üzerinde proliferasyon 
değerine sahip oldukları gözlemlenmiştir.
Anahtar kelimeler: Açiltiyoüre; antikanser; antiviral; 
tautomerizm; tiyoüre; 2-amino-1,3-tiyazol-4-on; 2-imino-1,3-
tiyazolidin-4-on.
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